AES 14

Drug Profile

AES 14

Alternative Names: Aesgen-14; E 6014; L-glutamine suspension - Aesgen; Saforis; Uptake-enhanced L-glutamine suspension

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MGI Pharma
  • Developer Eisai Co Ltd
  • Class Basic amino acids; Diamino amino acids; Neutral amino acids; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Stomatitis

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 15 May 2012 Discontinued - Phase-III for Stomatitis in USA (PO)
  • 01 Nov 2011 Phase III development is ongoing in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top